Anaphylaxis

Investigators found that peanut allergy immunotherapy was associated with a greater risk of anaphylaxis, epinephrine use, and serious adverse events compared to avoidance or placebo.

The first generation of food allergy treatments is nearing the market. What could be next is more individualized therapies.

What other specialties should become more involved in the network of care for allergic patients?

Is the US population having allergies diagnosed correctly, and are allergies on the rise?

Pediatric peanut allergy trials have proven successful. Now where do researchers look next?

What does the typical patient have to treat aside from their allergy, and what are their treatment goals?

Have current guidelines been fitted to consider the future of immunotherapy research?

UNC investigators consider the role current food allergy trials may play in addressing gaps of knowledge on patient individualization.

Why it may be critical to reassess dosing practices being practiced in investigative food allergy therapies.

About 9 of 10 patients were able to safely consume foods containing peanuts in an eight-year, longitudinal observational study.

The therapy was further assessed in asthmatic patients with comorbid chronic rhinosinusitis and with or without nasal polyposis.

UNC School of Medicine colleagues Edwin Kim, MD, MS, and Scott Commins, MD, PhD, explain how the discussion around food allergy care has progressed this year.

Investigative therapy PVX108 showed a favorable tolerability and safety profile in patients with peanut allergies.

Why both physicians and patients need to be on the same page when considering food allergy oral immunotherapy.

Why peanut allergy therapies are prioritized in early trials, and how far out are complimentary therapies to the ones currently being investigated.

A group of pediatric patients were able to sustain desensitization 4 weeks after stopping the daily oral immunotherapy.

How far in advances of care have we come, what issues are most pressing in the field now, and what specialties with be involved in future meetings?

The introduction of biologics such as dupilumab have opened avenues of care for patients with overlapping disease.

The biologic's indications for inflammatory diseases are greatly varied and still developing, and it owes some of that to recent advances in disease prognosis.

The AAAAI 2019 president explains why research is already dedicated toward improving investigative peanut allergens.

The Regeneron VP explains how dupilumab could possibly serve as a complimentary therapy to Aimmune's investigative food allergy therapy.

Results showed a statistically significant difference in responder rate between active treatment and placebo but didn’t meet a prespecified threshold for clinical significance.

The Program Chair explains how the meeting has improved over 3 decades, and highlights his favorite sessions to come at the 2019 meeting.

The intranasal epinephrine spray is being developed for use with Intravail, a nasal absorption enhancing technology.

Rapidly accumulating evidence indicates that delayed introduction of allergenic foods may have contributed to the unexplained rise in food allergy rates over the past 20 years.

Results may ease concerns for many physicians and patients who live in colder climates.

Researchers sought to balance the cost of autoinjectors with their lifesaving potential, and then boil the results down to an agreeable number. Here’s where they landed.

The FDA has approved a 0.15mg dosage of Symjepi, an epinephrine injection, for the emergency treatment of serious allergic reactions in children.

A generic version of the 0.3 mg- and 0.15 mg-strength injectors has been approved for the treatment of patients that include those with life-threatening allergic reactions.

Re-examination revealed that alpha-gal allergy resulted in a change in the identification of definitive anaphylaxis triggers in 25% of cases.